epristeride has been researched along with ly 300502 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bakshi, RK; Chang, B; Ellsworth, K; Harris, GS; Mosley, RT; Patel, GF; Rasmusson, GH; Tolman, RL | 1 |
| Baginsky, WF; Bakshi, RK; Bull, H; Chang, B; Cimis, G; Ellsworth, K; Harris, GS; Patel, GF; Rasmusson, GH; Tolman, RL | 1 |
| Audia, JE; Hirsch, KS; Jones, CD; Lawhorn, DE; McQuaid, LA; Neubauer, BL; Pennington, PA; Pike, AJ; Stamm, NB; Toomey, RE | 1 |
| Ballard, S; Blagg, J; Fox, D; Kenny, B | 1 |
1 review(s) available for epristeride and ly 300502
| Article | Year |
|---|---|
Pharmacological options in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlled Clinical Trials as Topic; Endothelins; Enzyme Inhibitors; Humans; Male; Prostate; Prostatic Hyperplasia; Receptors, Adrenergic, alpha; Structure-Activity Relationship | 1997 |
3 other study(ies) available for epristeride and ly 300502
| Article | Year |
|---|---|
4-Aza-3-oxo-5 alpha-androst-1-ene-17 beta-N-aryl-carboxamides as dual inhibitors of human type 1 and type 2 steroid 5 alpha-reductases. Dramatic effect of N-aryl substituents on type 1 and type 2 5 alpha-reductase inhibitory potency.
Topics: 5-alpha Reductase Inhibitors; Androstenes; Azasteroids; Humans; Molecular Conformation; Thermodynamics | 1995 |
4,7 beta-Dimethyl-4-azacholestan-3-one (MK-386) and related 4-azasteroids as selective inhibitors of human type 1 5 alpha-reductase.
Topics: 5-alpha Reductase Inhibitors; Azasteroids; Humans | 1994 |
Nonsteroidal inhibitors of human type I steroid 5-alpha-reductase.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Cell Line; Humans; Male; Quinolones; Structure-Activity Relationship | 1993 |